drugset / Trial / NCT00237497

Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00237497

Phase 3 Completed 275 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), compared to placebo with Zopiclone in adults with chronic insomnia

Timeline

Start
2005-07
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral
Comparator Zopiclone Small molecule 7.5 mg Oral

Indications

No indication recorded.